Efficacy and Safety of Darolutamide in Combination With ADT and Docetaxel by Disease Volume and Risk in the Phase 3 ARASENS Study

Video

Expert oncologist Matthew Smith, MD, PhD, reviews efficacy and safety data from the phase 3 ARASENS study combining darolutamide with ADT and docetaxel in patients with metastatic hormone-sensitive prostate cancer.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Jeffrey P. Townsend, PhD
Rohan Garje, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Carmen Guerra, MD, MSCE, FACP
Kara N. Maxwell, MD, PhD
Josep Maria Piulats Rodriguez, MD, PhD
Phillip J. Koo, MD
Phillip J. Koo, MD
Related Content
Antonio Alcaraz, PhD, chairman, Department of Urology, University Hospital Clinic of Barcelona

Enzalutamide Receives Go Ahead From European Commission in nmHSPC

April 24th 2024
Article
Neeraj Agarwal, MD

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

July 17th 2023
Podcast
OncLive On Air

Revisit Every OncLive On Air Episode from March 2024

April 19th 2024
Article
Andrew J. Armstrong, MD, MSc

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

June 15th 2023
Podcast
Cara Schafer, PhD, of Uniformed Services University of the Health Sciences

Proteogenomic Signatures Shed Light on Prostate Cancer Recurrence Risk in Select Ancestries

April 10th 2024
Article
Ruben Olivares, MD

Patient Selection Key for Focal Therapy in Intermediate Prostate Cancer

April 5th 2024
Article